Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory Characteristics
This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory r...
Saved in:
Published in | Clinical infectious diseases Vol. 37; no. 8; pp. 1084 - 1092 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Chicago, IL
The University of Chicago Press
15.10.2003
University of Chicago Press |
Subjects | |
Online Access | Get full text |
ISSN | 1058-4838 1537-6591 1537-6591 |
DOI | 10.1086/378747 |
Cover
Loading…
Abstract | This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (± standard deviation) was 46.9 ± 19.4 years, and the ratio of male to female patients was 4 : 1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01–0.63). |
---|---|
AbstractList | This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (± standard deviation) was 46.9 ± 19.4 years, and the ratio of male to female patients was 4 : 1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01–0.63). This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age ( plus or minus standard deviation) was 46.9 plus or minus 19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63). This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63).This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63). This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in Saudi Arabia from 26 August 2000 through 22 September 2001. A total of 886 cases were reported. Of 834 reported cases for which laboratory results were available, 81.9% were laboratory confirmed, of which 51.1% were positive for only RVF immunoglobulin M, 35.7% were positive for only RVF antigen, and 13.2% were positive for both. The mean age (+/- standard deviation) was 46.9+/-19.4 years, and the ratio of male to female patients was 4:1. Clinical and laboratory features included fever (92.6% of patients), nausea (59.4%), vomiting (52.6%), abdominal pain (38.0%), diarrhea (22.1%), jaundice (18.1%), neurological manifestations (17.1%), hemorrhagic manifestations (7.1%), vision loss or scotomas (1.5%), elevated liver enzyme levels (98%), elevated lactate dehydrogenase level (60.2%), thrombocytopenia (38.4%), leukopenia (39.7%), renal impairment or failure (27.8%), elevated creatine kinase level (27.3%), and severe anemia (15.1%). The mortality rate was 13.9%. Bleeding, neurological manifestations, and jaundice were independently associated with a high mortality rate. Patients with leukopenia had significantly a lower mortality rate than did those with a normal or high leukocyte count (2.3% vs. 27.9%; odds ratio, 0.09; 95% confidence interval, 0.01-0.63). |
Author | Al-Rabeah, Abdullah M. Turkistani, Adel M. Al-Sayed, Mohammad O. Al-Mazrou, Yagob Y. Mishkhas, Amin A. Abodahish, Abdullah A. Khan, Ali S. Shobokshi, Osama Ksiazek, Thomas G. Madani, Tariq A. Al-Jeffri, Mohammad H. |
Author_xml | – sequence: 1 givenname: Tariq A. surname: Madani fullname: Madani, Tariq A. email: taamadani@yahoo.com organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 2 givenname: Yagob Y. surname: Al-Mazrou fullname: Al-Mazrou, Yagob Y. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 3 givenname: Mohammad H. surname: Al-Jeffri fullname: Al-Jeffri, Mohammad H. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 4 givenname: Amin A. surname: Mishkhas fullname: Mishkhas, Amin A. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 5 givenname: Abdullah M. surname: Al-Rabeah fullname: Al-Rabeah, Abdullah M. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 6 givenname: Adel M. surname: Turkistani fullname: Turkistani, Adel M. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 7 givenname: Mohammad O. surname: Al-Sayed fullname: Al-Sayed, Mohammad O. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 8 givenname: Abdullah A. surname: Abodahish fullname: Abodahish, Abdullah A. organization: Ministry of Health, Riyadh, Saudi Arabia – sequence: 9 givenname: Ali S. surname: Khan fullname: Khan, Ali S. organization: Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 10 givenname: Thomas G. surname: Ksiazek fullname: Ksiazek, Thomas G. organization: Special Pathogens Branch, Division of Viral and Rickettsial Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia – sequence: 11 givenname: Osama surname: Shobokshi fullname: Shobokshi, Osama organization: Ministry of Health, Riyadh, Saudi Arabia |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15235401$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/14523773$$D View this record in MEDLINE/PubMed |
BookMark | eNqF0ltrFDEUB_AgFXtRP4HI-KBPHU0mtxnfytB2SxcEL7X0JZzJJJo6O1mTjLjf3shsu6CITzlwfjmB888h2hv9aBB6SvBrgmvxhspaMvkAHRBOZSl4Q_ZyjXldsprW--gwxluMCakxf4T2CeMVlZIeIPPe2VRcwTCYTXFmfphQnK5db1ZOF24sPsDUu-IkQOfg7V3HD_6L0zAcF-3gxrmCsS-W0PkAyYdN0X6FADqZ4GJyOj5GDy0M0TzZnkfo09npx3ZRLt-dX7Qny1IzTlNpSVdpI5gQnGBrq8qSHjSnvGsAWwa1lKaTFXDJLBUM14TX0BFmuBWME0mP0Kt57jr475OJSa1c1GYYYDR-ikrmmwRL_F9IGtJQIpoMn2_h1K1Mr9bBrSBs1N0GM3i5BRDzJmyAUbu4c5lxhsnuRR18jMHYHcHqd4RqjjDD4z-gdgmS82MK4Ia_-YuZ-2n975HPZnMbczr3iuWvIaoqt8u5ncMyP-_bEL4pIankanF9oz5ftzfnV4tGXdJf1yW8bw |
CODEN | CIDIEL |
CitedBy_id | crossref_primary_10_1371_journal_pntd_0011677 crossref_primary_10_2987_10_6070_1 crossref_primary_10_3402_iee_v5_28024 crossref_primary_10_1371_journal_pntd_0008143 crossref_primary_10_3923_ajava_2015_781_788 crossref_primary_10_1002_vms3_135 crossref_primary_10_1371_journal_pone_0305521 crossref_primary_10_1016_j_celrep_2018_12_001 crossref_primary_10_1080_13550280591002450 crossref_primary_10_3390_pathogens13100856 crossref_primary_10_20473_javest_V5_I1_2024_78_82 crossref_primary_10_1016_j_virol_2011_08_024 crossref_primary_10_1186_s12985_018_1071_y crossref_primary_10_1016_j_respe_2015_03_124 crossref_primary_10_1371_journal_pone_0251263 crossref_primary_10_1371_journal_pntd_0007979 crossref_primary_10_1128_JVI_01662_17 crossref_primary_10_14202_vetworld_2022_1990_1995 crossref_primary_10_1371_journal_pntd_0010339 crossref_primary_10_3390_vetsci7030103 crossref_primary_10_1128_mSphere_00798_20 crossref_primary_10_1371_journal_ppat_1003922 crossref_primary_10_2987_14_6441R_1 crossref_primary_10_1080_1040841X_2018_1446901 crossref_primary_10_3201_eid2811_220364 crossref_primary_10_3390_ijms232012492 crossref_primary_10_1128_JVI_01506_21 crossref_primary_10_3390_v11010035 crossref_primary_10_1007_s11030_023_10702_x crossref_primary_10_1126_sciadv_adh2264 crossref_primary_10_1371_journal_pntd_0002156 crossref_primary_10_1016_j_medmal_2010_12_007 crossref_primary_10_1128_jvi_00415_23 crossref_primary_10_1128_JVI_02095_06 crossref_primary_10_3390_tropicalmed5020089 crossref_primary_10_1089_vbz_2010_0084 crossref_primary_10_1186_s13620_016_0065_6 crossref_primary_10_1016_j_antiviral_2014_03_008 crossref_primary_10_1371_journal_ppat_1007833 crossref_primary_10_1016_j_copbio_2008_10_009 crossref_primary_10_1093_cid_cir732 crossref_primary_10_2903_j_efsa_2020_6292 crossref_primary_10_1016_j_vaccine_2013_09_029 crossref_primary_10_1016_j_vaccine_2010_04_048 crossref_primary_10_1371_journal_pone_0065786 crossref_primary_10_1080_21505594_2024_2384563 crossref_primary_10_3390_v15122369 crossref_primary_10_1038_s41541_017_0021_9 crossref_primary_10_1155_2018_4956378 crossref_primary_10_1371_journal_pntd_0006627 crossref_primary_10_3390_pathogens13020159 crossref_primary_10_1016_j_aspen_2017_12_001 crossref_primary_10_1016_j_vaccine_2017_04_085 crossref_primary_10_1016_j_medmal_2010_12_010 crossref_primary_10_4269_ajtmh_2010_09_0293 crossref_primary_10_1016_j_jcv_2012_07_004 crossref_primary_10_1186_s12985_024_02602_9 crossref_primary_10_1016_j_onehlt_2023_100583 crossref_primary_10_1111_tbed_12267 crossref_primary_10_1371_journal_pntd_0000763 crossref_primary_10_1371_journal_pntd_0006175 crossref_primary_10_1093_jmedent_45_1_102 crossref_primary_10_1007_s40588_018_0110_1 crossref_primary_10_3390_microorganisms10010092 crossref_primary_10_1371_journal_pntd_0005082 crossref_primary_10_1186_1471_2334_6_135 crossref_primary_10_1186_s13071_016_1383_y crossref_primary_10_1016_j_virol_2015_12_003 crossref_primary_10_1016_S2222_1808_15_60993_8 crossref_primary_10_3390_pathogens13070582 crossref_primary_10_1371_journal_pone_0066626 crossref_primary_10_1186_s12936_023_04467_9 crossref_primary_10_1128_JVI_02341_13 crossref_primary_10_1016_j_idc_2019_08_003 crossref_primary_10_1089_vbz_2014_1686 crossref_primary_10_4269_ajtmh_2010_09_0288 crossref_primary_10_1371_journal_pntd_0004314 crossref_primary_10_1007_s12250_016_3876_4 crossref_primary_10_1016_j_intimp_2018_09_002 crossref_primary_10_1093_jme_tjad060 crossref_primary_10_3390_v10040191 crossref_primary_10_1186_s13071_019_3417_8 crossref_primary_10_1371_journal_pntd_0009273 crossref_primary_10_1016_j_jviromet_2019_113701 crossref_primary_10_1016_j_indcrop_2025_120744 crossref_primary_10_1177_0309133313478315 crossref_primary_10_1016_j_cll_2004_05_001 crossref_primary_10_1016_S1155_1976_12_59748_2 crossref_primary_10_1017_dmp_2025_27 crossref_primary_10_1371_journal_pntd_0001557 crossref_primary_10_1016_S2222_1808_15_60944_6 crossref_primary_10_1128_JVI_02055_15 crossref_primary_10_1371_journal_pntd_0007898 crossref_primary_10_1093_jmedent_47_5_884 crossref_primary_10_1002_vms3_848 crossref_primary_10_1016_S0213_005X_05_75042_4 crossref_primary_10_1128_JVI_01519_08 crossref_primary_10_3389_fmicb_2020_590732 crossref_primary_10_1016_j_peptides_2021_170570 crossref_primary_10_1016_j_virol_2009_11_001 crossref_primary_10_1111_zph_12153 crossref_primary_10_1002_vms3_1238 crossref_primary_10_1016_j_puhe_2015_07_034 crossref_primary_10_1186_1743_422X_6_125 crossref_primary_10_3390_v8050145 crossref_primary_10_1016_j_vaccine_2012_03_027 crossref_primary_10_1128_JVI_01394_19 crossref_primary_10_1007_s11250_017_1359_8 crossref_primary_10_11603_1681_2727_2019_4_10964 crossref_primary_10_1016_j_virol_2012_05_012 crossref_primary_10_4102_ojvr_v86i1_1683 crossref_primary_10_1016_j_bbamem_2014_04_015 crossref_primary_10_1128_JCM_00936_07 crossref_primary_10_1021_acsomega_1c06513 crossref_primary_10_1371_journal_pntd_0005226 crossref_primary_10_1371_journal_pntd_0003045 crossref_primary_10_1371_journal_pone_0116722 crossref_primary_10_1371_journal_pntd_0001423 crossref_primary_10_1371_journal_ppat_1010649 crossref_primary_10_4269_ajtmh_2010_09_0463 crossref_primary_10_7759_cureus_48284 crossref_primary_10_3390_v11020139 crossref_primary_10_1371_journal_pntd_0010482 crossref_primary_10_1016_j_vaccine_2017_10_036 crossref_primary_10_1186_s12917_020_02455_8 crossref_primary_10_1089_vbz_2010_0040 crossref_primary_10_1111_tbed_12903 crossref_primary_10_2987_5645_1 crossref_primary_10_3390_v14112470 crossref_primary_10_1073_pnas_1112149108 crossref_primary_10_3389_fmicb_2015_00787 crossref_primary_10_1016_j_antiviral_2014_10_001 crossref_primary_10_3390_v15020306 crossref_primary_10_3389_fmicb_2015_01509 crossref_primary_10_1016_j_cell_2024_09_008 crossref_primary_10_3201_eid1606_091266 crossref_primary_10_1128_JVI_02501_07 crossref_primary_10_1016_j_vaccine_2011_02_037 crossref_primary_10_1086_383576 crossref_primary_10_1016_j_cell_2021_09_001 crossref_primary_10_3390_v6031410 crossref_primary_10_1007_s00436_025_08457_5 crossref_primary_10_1371_journal_pone_0217497 crossref_primary_10_1371_journal_pntd_0010233 crossref_primary_10_2217_fvl_2017_0060 crossref_primary_10_1111_2049_632X_12157 crossref_primary_10_3390_pathogens10060708 crossref_primary_10_1099_jgv_0_001522 crossref_primary_10_1038_s41541_019_0138_0 crossref_primary_10_1128_mSphere_00090_17 crossref_primary_10_4236_ojpm_2013_31004 crossref_primary_10_1371_journal_pntd_0001529 crossref_primary_10_1186_s12985_016_0509_3 crossref_primary_10_1603_ME13049 crossref_primary_10_1007_s12010_017_2592_3 crossref_primary_10_3390_v8070194 crossref_primary_10_1186_s41182_019_0178_1 crossref_primary_10_1016_j_onehlt_2022_100470 crossref_primary_10_1111_tbed_14415 crossref_primary_10_1007_s11250_023_03765_3 crossref_primary_10_1371_journal_pntd_0006412 crossref_primary_10_2222_jsv_70_3 crossref_primary_10_1186_s12936_016_1581_2 crossref_primary_10_1177_0300985809354350 crossref_primary_10_1371_journal_pntd_0003095 crossref_primary_10_15585_mmwr_mm6543a5 crossref_primary_10_3390_v2030731 crossref_primary_10_1093_jme_tjv093 crossref_primary_10_1016_j_ophtha_2004_09_018 crossref_primary_10_1186_s12985_024_02377_z crossref_primary_10_4102_ojvr_v79i2_466 crossref_primary_10_3390_v15112140 crossref_primary_10_1099_jgv_0_000765 crossref_primary_10_1371_journal_pone_0309288 crossref_primary_10_3390_v12030259 crossref_primary_10_3390_v13040709 crossref_primary_10_1186_1743_422X_7_97 crossref_primary_10_1673_031_011_17601 crossref_primary_10_4102_jsava_v88_1379 crossref_primary_10_1016_S1245_1789_08_70235_X crossref_primary_10_1038_s41598_024_53774_x crossref_primary_10_1371_journal_pntd_0003536 crossref_primary_10_3390_v11100919 crossref_primary_10_2987_08_5791_1 crossref_primary_10_1016_j_vetmic_2014_04_007 crossref_primary_10_1097_IPC_0b013e31814b1b36 crossref_primary_10_1016_j_coviro_2012_02_017 crossref_primary_10_1016_j_epidem_2020_100409 crossref_primary_10_1093_ofid_ofw200 crossref_primary_10_2987_11_6176_1 crossref_primary_10_1016_j_ijid_2009_03_029 crossref_primary_10_1089_vbz_2019_2532 crossref_primary_10_1093_infdis_jiaf060 crossref_primary_10_2139_ssrn_1027752 crossref_primary_10_1016_j_vaccine_2017_04_024 crossref_primary_10_1128_JCM_01412_08 crossref_primary_10_1371_journal_pntd_0006474 crossref_primary_10_1038_srep05824 crossref_primary_10_1007_s11481_010_9234_7 crossref_primary_10_1038_s41598_023_29023_y crossref_primary_10_1017_S0950268807009806 crossref_primary_10_3389_fimmu_2022_1084230 crossref_primary_10_1186_s12985_017_0811_8 crossref_primary_10_1172_jci_insight_180151 crossref_primary_10_3201_eid1712_110658 crossref_primary_10_1186_1746_6148_10_92 crossref_primary_10_1128_JCM_01905_08 crossref_primary_10_1016_j_antiviral_2018_05_009 crossref_primary_10_1016_j_antiviral_2009_10_008 crossref_primary_10_1371_journal_pntd_0001229 crossref_primary_10_2987_8756_971X_2007_23_226_POAAIL_2_0_CO_2 crossref_primary_10_1111_tbed_12331 crossref_primary_10_1093_infdis_jir249 crossref_primary_10_3389_fmicb_2023_1114226 crossref_primary_10_1371_journal_pntd_0002430 crossref_primary_10_1016_j_jiph_2012_11_011 crossref_primary_10_1038_emi_2013_81 crossref_primary_10_1016_j_jviromet_2011_12_013 crossref_primary_10_1371_journal_pntd_0002670 crossref_primary_10_1146_annurev_virology_091919_065806 crossref_primary_10_1371_journal_pntd_0002435 crossref_primary_10_3390_v13061079 crossref_primary_10_1136_bcr_2016_216054 crossref_primary_10_1016_j_virol_2007_01_046 crossref_primary_10_1371_journal_pntd_0009852 crossref_primary_10_1016_j_jim_2018_06_006 crossref_primary_10_1371_journal_pntd_0006460 crossref_primary_10_1007_s13546_011_0262_y crossref_primary_10_1080_24725579_2024_2370243 crossref_primary_10_1089_vbz_2010_0245 crossref_primary_10_1177_0300985820954549 crossref_primary_10_1111_tra_12393 crossref_primary_10_1371_journal_ppat_1002661 crossref_primary_10_1016_j_vaccine_2015_08_020 crossref_primary_10_1371_journal_pntd_0004840 crossref_primary_10_3201_eid1902_120941 crossref_primary_10_1016_j_tmaid_2008_09_008 crossref_primary_10_1371_journal_pone_0077461 crossref_primary_10_4102_ojvr_v87i1_1877 crossref_primary_10_1016_j_vaccine_2011_04_043 crossref_primary_10_1089_vbz_2019_2554 crossref_primary_10_1128_JVI_01270_18 crossref_primary_10_1016_j_actatropica_2012_12_013 crossref_primary_10_1088_1758_5090_ad4c0b crossref_primary_10_1016_j_virol_2011_09_023 crossref_primary_10_1186_s12941_020_0346_5 crossref_primary_10_1038_emi_2014_71 crossref_primary_10_3923_javaa_2010_258_265 crossref_primary_10_1038_s41598_020_65683_w crossref_primary_10_3201_eid1408_080082 crossref_primary_10_1089_vbz_2015_1774 crossref_primary_10_1016_j_vaccine_2015_12_030 crossref_primary_10_1128_CVI_00114_15 crossref_primary_10_2217_fvl_14_62 crossref_primary_10_1093_ilar_ilx023 crossref_primary_10_1590_1678_4685_gmb_2019_0240 crossref_primary_10_1016_j_antiviral_2017_04_011 crossref_primary_10_1099_jgv_0_001296 crossref_primary_10_1099_jgv_0_001970 crossref_primary_10_1016_j_jviromet_2019_04_011 crossref_primary_10_3390_vaccines10111794 crossref_primary_10_18357_anthropologica66120242646 crossref_primary_10_1007_s00705_021_05083_1 crossref_primary_10_3201_eid1902_120834 crossref_primary_10_1371_journal_pntd_0005002 crossref_primary_10_1016_j_cll_2017_01_004 crossref_primary_10_1016_j_actatropica_2012_04_007 crossref_primary_10_1016_j_smallrumres_2011_03_011 crossref_primary_10_1080_21645515_2019_1627820 crossref_primary_10_1007_s11250_019_01978_z crossref_primary_10_1016_j_microb_2023_100016 crossref_primary_10_24880_maeuvfd_260789 crossref_primary_10_1080_13550280591002496 crossref_primary_10_1371_journal_pone_0259466 crossref_primary_10_1371_journal_pntd_0002244 crossref_primary_10_1016_j_ijid_2020_07_043 crossref_primary_10_1186_s12917_017_0993_8 crossref_primary_10_1371_journal_pntd_0005756 crossref_primary_10_1089_vbz_2019_2458 crossref_primary_10_1186_1471_2334_13_136 crossref_primary_10_4161_hv_20202 crossref_primary_10_1128_jvi_00853_23 crossref_primary_10_1371_journal_pntd_0007258 crossref_primary_10_1177_20503121241229847 crossref_primary_10_3389_fvets_2024_1489815 crossref_primary_10_1371_journal_pone_0209929 crossref_primary_10_1146_annurev_virology_093022_011544 crossref_primary_10_1038_srep20617 crossref_primary_10_3389_fimmu_2022_907675 crossref_primary_10_1371_journal_pntd_0001265 crossref_primary_10_1038_s41541_020_00218_y crossref_primary_10_1371_journal_pntd_0002237 crossref_primary_10_1016_j_prevetmed_2023_106071 crossref_primary_10_1371_journal_pntd_0002356 crossref_primary_10_1073_pnas_1607948114 crossref_primary_10_1136_bmjgh_2020_002694 crossref_primary_10_1007_s13149_011_0165_1 crossref_primary_10_3390_v16071148 crossref_primary_10_1016_j_antiviral_2009_08_002 crossref_primary_10_1371_journal_pntd_0000725 crossref_primary_10_1371_journal_pone_0128215 crossref_primary_10_4102_ojvr_v88i1_1877 crossref_primary_10_4269_ajtmh_2010_83s2a01 crossref_primary_10_1371_journal_pntd_0005731 crossref_primary_10_1039_C7CP02695A crossref_primary_10_3389_fneur_2021_634827 crossref_primary_10_1017_S0950268810001020 crossref_primary_10_1371_journal_ppat_1010231 crossref_primary_10_1093_jhered_esv087 crossref_primary_10_4001_003_022_0402 crossref_primary_10_1016_j_virusres_2012_07_019 crossref_primary_10_1128_JVI_06190_11 crossref_primary_10_1016_j_sjbs_2016_07_003 crossref_primary_10_4254_wjh_v11_i1_37 crossref_primary_10_1016_j_idc_2012_02_003 crossref_primary_10_1186_s12879_015_1099_1 crossref_primary_10_47485_2767_5416_1084 crossref_primary_10_2460_ajvr_71_5_522 crossref_primary_10_1016_j_virol_2018_10_021 crossref_primary_10_1051_vetres_2010033 crossref_primary_10_1038_s41598_023_42596_y crossref_primary_10_3389_fitd_2023_1240420 crossref_primary_10_1186_1743_422X_9_139 crossref_primary_10_1016_j_virol_2010_08_016 crossref_primary_10_14202_IJOH_2021_237_245 crossref_primary_10_1128_JVI_06046_11 crossref_primary_10_1016_j_coviro_2017_10_007 crossref_primary_10_1038_gene_2014_79 crossref_primary_10_1128_AAC_03595_14 |
Cites_doi | 10.1016/0140-6736(93)92128-G 10.1016/S0923-2516(89)80081-0 10.1086/514321 10.3201/eid0812.020195 10.3201/eid0802.010023 10.1002/path.1700340418 10.1016/0035-9203(79)90004-X 10.1016/0035-9203(79)90006-3 10.1016/S0923-2516(89)80090-1 |
ContentType | Journal Article |
Copyright | Copyright 2003 The Infectious Diseases Society of America 2003 by the Infectious Diseases Society of America 2003 2004 INIST-CNRS |
Copyright_xml | – notice: Copyright 2003 The Infectious Diseases Society of America – notice: 2003 by the Infectious Diseases Society of America 2003 – notice: 2004 INIST-CNRS |
DBID | BSCLL AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
DOI | 10.1086/378747 |
DatabaseName | Istex CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Virology and AIDS Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) AIDS and Cancer Research Abstracts Virology and AIDS Abstracts MEDLINE - Academic |
DatabaseTitleList | AIDS and Cancer Research Abstracts MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1537-6591 |
EndPage | 1092 |
ExternalDocumentID | 14523773 15235401 10_1086_378747 10.1086/378747 4483622 ark_67375_HXZ_WXCZGVH9_K |
Genre | Journal Article |
GeographicLocations | Saudi Arabia Asia Yemen |
GeographicLocations_xml | – name: Saudi Arabia – name: Yemen |
GroupedDBID | --- ..I .2P .GJ .I3 .ZR 08P 0R~ 1TH 29B 2AX 2WC 36B 3O- 4.4 48X 53G 5GY 5RE 5VS 5WD 6J9 AABZA AACGO AACZT AAJKP AAJQQ AAMVS AANCE AAOGV AAPQZ AAPXW AAQQT AARHZ AAUAY AAUQX AAVAP ABBHK ABDFA ABEJV ABEUO ABGNP ABIXL ABJNI ABLJU ABNGD ABNHQ ABOCM ABPLY ABPQP ABPTD ABQLI ABQNK ABTLG ABVGC ABWST ABXSQ ABXVV ACGFO ACGFS ACHIC ACPRK ACUFI ACUKT ACUTO ACYHN ADBBV ADGZP ADHKW ADHZD ADIPN ADNBA ADQBN ADQXQ ADRTK ADULT ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AEMQT AENEX AENZO AEPUE AETBJ AEUPB AEWNT AEXZC AFFNX AFFZL AFIYH AFOFC AFRAH AFXAL AGINJ AGORE AGQPQ AGQXC AGSYK AGUTN AHMBA AHMMS AHXPO AI. AIAGR AJBYB AJEEA AJNCP ALMA_UNASSIGNED_HOLDINGS ALUQC ALXQX APIBT APWMN AQKUS AQVQM ASPBG ATGXG AVWKF AXUDD AZFZN BAWUL BAYMD BCRHZ BEYMZ BHONS BSCLL BTRTY BVRKM C1A C45 CDBKE CS3 CZ4 DAKXR DCCCD DIK DILTD DU5 D~K E3Z EBS EE~ EJD EMOBN ENERS F5P F9B FECEO FEDTE FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC H5~ HAR HQ3 HTVGU HVGLF HW0 HZ~ IOX IPSME J21 J5H JAAYA JBMMH JENOY JHFFW JKQEH JLS JLXEF JPM JSG JST JXSIZ KAQDR KBUDW KOP KSI KSN L7B MHKGH MJL ML0 N4W N9A NGC NOMLY NOYVH NU- NVLIB O0~ O9- OAUYM OAWHX OCZFY ODMLO ODZKP OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PB- PEELM PQQKQ Q1. Q5Y QBD RD5 ROX ROZ RUSNO RW1 RXO SA0 SJN TCURE TEORI TJX TMA TR2 VH1 W8F X7H YAYTL YKOAZ YXANX ZGI ~91 ~S- AAYOK AASNB ADACV ADJQC ADRIX AFXEN DOOOF ESX JSODD M49 AAYXX CITATION 1KJ 70D AAPGJ AAPNW AAWDT ABKDP ABNKS ABSMQ ABZBJ ACFRR ACPQN ACUTJ ACVCV ACZBC ADEYI ADMTO ADOCK AEKPW AFFQV AFSHK AFYAG AGKEF AGKRT AGMDO AHGBF AIJHB AJDVS APJGH AQDSO AVNTJ BZKNY EIHJH H13 IQODW MBLQV OBFPC O~Y Y6R CGR CUY CVF ECM EIF NPM 7U9 H94 7X8 |
ID | FETCH-LOGICAL-c453t-f1b2ce6466510ff22f1dac535b9a0f4a877eb72a574f36408158ab14e5f645173 |
ISSN | 1058-4838 1537-6591 |
IngestDate | Fri Sep 05 04:28:58 EDT 2025 Tue Aug 05 09:42:27 EDT 2025 Wed Feb 19 01:51:05 EST 2025 Mon Jul 21 09:13:39 EDT 2025 Thu Apr 24 23:11:06 EDT 2025 Tue Jul 01 04:28:39 EDT 2025 Wed Sep 11 04:49:12 EDT 2024 Thu Jun 19 15:26:07 EDT 2025 Tue Aug 05 16:49:09 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 8 |
Keywords | Prognosis Male Hemopathy Epidemiology Visual field disease Vomiting Cohort study Arbovirus disease Intestinal disease Female Carbohydrate Age Kidney disease Epidemic Rift valley fever Human Immunoglobulins Urinary system disease Critically ill Characteristic Diarrhea Nausea Standards Infection Antigen Case study Symptomatology Eye disease Metabolic disorder Platelet Viral disease Digestive diseases Lactic acid |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c453t-f1b2ce6466510ff22f1dac535b9a0f4a877eb72a574f36408158ab14e5f645173 |
Notes | ark:/67375/HXZ-WXCZGVH9-K istex:65C0FF02C3A9B103128EA4822B7B2D0A6792673A ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 ObjectType-Article-1 ObjectType-Feature-2 |
OpenAccessLink | https://academic.oup.com/cid/article-pdf/37/8/1084/5910138/37-8-1084.pdf |
PMID | 14523773 |
PQID | 19193169 |
PQPubID | 23462 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_75741070 proquest_miscellaneous_19193169 pubmed_primary_14523773 pascalfrancis_primary_15235401 crossref_primary_10_1086_378747 crossref_citationtrail_10_1086_378747 oup_primary_10_1086_378747 jstor_primary_4483622 istex_primary_ark_67375_HXZ_WXCZGVH9_K |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2003-10-15 |
PublicationDateYYYYMMDD | 2003-10-15 |
PublicationDate_xml | – month: 10 year: 2003 text: 2003-10-15 day: 15 |
PublicationDecade | 2000 |
PublicationPlace | Chicago, IL |
PublicationPlace_xml | – name: Chicago, IL – name: United States |
PublicationTitle | Clinical infectious diseases |
PublicationTitleAbbrev | Clinical Infectious Diseases |
PublicationTitleAlternate | Clinical Infectious Diseases |
PublicationYear | 2003 |
Publisher | The University of Chicago Press University of Chicago Press |
Publisher_xml | – name: The University of Chicago Press – name: University of Chicago Press |
References | Anderson (12_5335291) 1989; 140 Woods (17_16961167) 2002; 8 Zaki (13_15800967) 1995; 146 (10_26479589) 1999; 179 van Velden (15_4336408) 1977; 51 (9_5982062) 1998; 47 Shoemaker (11_17384930) 2002; 8 (2_23806421) 1931; 34 El-Gebaly (5_7886887) 1978; 53 Meegan (6_8068707) 1979; 73 (14_43933339) 1979; 73 Arthur (8_14505517) 1993; 342 Digoutte (7_5228285) 1989; 140 15156493 - Clin Infect Dis. 2004 May 15;38(10):1503 |
References_xml | – volume: 342 start-page: 1149 issn: 0140-6736 issue: 8880 year: 1993 ident: 8_14505517 publication-title: Lancet doi: 10.1016/0140-6736(93)92128-G – volume: 140 start-page: 27 issn: 0923-2516 issue: 1 year: 1989 ident: 7_5228285 publication-title: Research in virology doi: 10.1016/S0923-2516(89)80081-0 – volume: 179 start-page: 177 issn: 0022-1899 year: 1999 ident: 10_26479589 publication-title: Journal of Infectious Diseases doi: 10.1086/514321 – volume: 8 start-page: 1415 issn: 1080-6040 issue: 12 year: 2002 ident: 11_17384930 publication-title: Emerging infectious diseases doi: 10.3201/eid0812.020195 – volume: 8 start-page: 138 issn: 1080-6040 issue: 2 year: 2002 ident: 17_16961167 publication-title: Emerging infectious diseases doi: 10.3201/eid0802.010023 – volume: 47 start-page: 261 issn: 0149-2195 issue: 13 year: 1998 ident: 9_5982062 publication-title: MMWR. Morbidity and mortality weekly report – volume: 34 start-page: 545 issn: 0368-3494 year: 1931 ident: 2_23806421 publication-title: The Journal of pathology and bacteriology doi: 10.1002/path.1700340418 – volume: 51 start-page: 867 issn: 0038-2469 issue: 24 year: 1977 ident: 15_4336408 publication-title: South African medical journal. Suid-Afrikaanse tydskrif vir geneeskunde – volume: 73 start-page: 618 issn: 0035-9203 issue: 6 year: 1979 ident: 6_8068707 publication-title: Transactions of The Royal Society of Tropical Medicine and Hygiene doi: 10.1016/0035-9203(79)90004-X – volume: 146 start-page: 552 issn: 0002-9440 issue: 3 year: 1995 ident: 13_15800967 publication-title: American Journal Of Pathology – volume: 53 start-page: 137 issn: 0013-2446 issue: 3-4 year: 1978 ident: 5_7886887 publication-title: The Journal of the Egyptian Public Health Association – volume: 73 start-page: 630 issn: 0035-9203 issue: 6 year: 1979 ident: 14_43933339 publication-title: Transactions of The Royal Society of Tropical Medicine and Hygiene doi: 10.1016/0035-9203(79)90006-3 – volume: 140 start-page: 129 issn: 0923-2516 issue: 2 year: 1989 ident: 12_5335291 publication-title: Research in virology doi: 10.1016/S0923-2516(89)80090-1 – reference: 15156493 - Clin Infect Dis. 2004 May 15;38(10):1503 |
SSID | ssj0011805 |
Score | 2.3220189 |
Snippet | This cohort descriptive study summarizes the epidemiological, clinical, and laboratory characteristics of the Rift Valley fever (RVF) epidemic that occurred in... |
SourceID | proquest pubmed pascalfrancis crossref oup jstor istex |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1084 |
SubjectTerms | Adolescent Adult Aged Aged, 80 and over Antigens Arboviroses Biological and medical sciences Child Disease Outbreaks Diseases of visual field, optic nerve, optic chiasma and optic tracts Enzymes Epidemics Epidemiology Female Fever Fever - etiology Geographic regions Human viral diseases Humans Infections Infectious diseases Major Articles Male Medical sciences Middle Aged Miscellaneous Mortality Nausea - etiology Ophthalmology Rift Valley Fever - epidemiology Rift Valley Fever - physiopathology Rift Valley fever virus Rift valleys Saudi Arabia - epidemiology Tropical viral diseases Viral diseases Viruses Vomiting - etiology Yemen - epidemiology |
Title | Rift Valley Fever Epidemic in Saudi Arabia: Epidemiological, Clinical, and Laboratory Characteristics |
URI | https://api.istex.fr/ark:/67375/HXZ-WXCZGVH9-K/fulltext.pdf https://www.jstor.org/stable/4483622 https://www.ncbi.nlm.nih.gov/pubmed/14523773 https://www.proquest.com/docview/19193169 https://www.proquest.com/docview/75741070 |
Volume | 37 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbKJiEkhLgM6IDhB-AlSxUntpPwVpWNwggP0I1uL5GTOqza2o5eEOxv8Qc5tuP0MsrtJWrji6x8n4_Psc_xQehZAJMI5hhxQxkHYKDkhRtlAXNzzgWFJSanXAUnJ-95-5C-7bJurfZjwWtpNs0a-eUv40r-B1V4B7iqKNl_QLbqFF7Ab8AXnoAwPP8K4w_9YuocqWwo3519-VX5a5iEr7naxvgoZr2-0xyLrK8T8OzNk8EqZPQWaRkXaX043xlKqHP31vJNzotKrG1VeXLNJvagp9LQE9Ez2aKcDljjX5xmo6LWuZuIy_FopqW_-DzKnOPFQh1bplsmo1MxGIie067Kk_7k9KwMQmsO1F5NY2nfQnvAmcjNho18-7PviRLJHtNbnkZKSyumQ5czk-fLynFzeUzJ12hBKBPPZKErF3jimex7VxYPT59lBSDCzCWgKxdxr1a5hjZ9sE1UvpBXbw6qoysSab_ZatgLCa1MuyUNaFNN5m_WGdZGWd68EBOAsTC5VdYbP1oJ6txGt0rrBTcNFe-gmhzeRdeT0j_jHpKKkdgwEmtGYstI3B9izUhsGPkSr_BxF1te7WLgIp5zEa9wcQsd7u91Wm23TOTh5pQFU7cgmZ9LTjmHFaAofL8gPZGzgGWx8AoqojCUWegLFtIi4BS0VBaJjFDJCk4ZCYP7aGM4GsqHCMd5xmKPQkOwBHjYy0CFFSyPIiHhH_fq6Ln9uGle3nKvkq2cp9rbIuKpAaGOnlb1Lsy9LldqvNDYVMVifKa8IEOWtrsn6adu6-T1UTtOD-poS4NXVaQAO_f9OtoGMNf2vrOE8bwa89VWLIEBWtBTkPjqGE8MJUzolMRgdBEer68RwocksJbX0QPDlnnvFLoPw2D7d2N7hG7MJ-xjtDEdz-QTUL2n2Y6m-k_e5NOS |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Rift+Valley+Fever+Epidemic+in+Saudi+Arabia%3A+Epidemiological%2C+Clinical%2C+and+Laboratory+Characteristics&rft.jtitle=Clinical+infectious+diseases&rft.au=Madani%2C+Tariq+A.&rft.au=Al-Mazrou%2C+Yagob+Y.&rft.au=Al-Jeffri%2C+Mohammad+H.&rft.au=Mishkhas%2C+Amin+A.&rft.date=2003-10-15&rft.pub=The+University+of+Chicago+Press&rft.issn=1058-4838&rft.eissn=1537-6591&rft.volume=37&rft.issue=8&rft.spage=1084&rft.epage=1092&rft_id=info:doi/10.1086%2F378747&rft.externalDocID=10.1086%2F378747 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1058-4838&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1058-4838&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1058-4838&client=summon |